Biofrontera Stock Today
| BFRI Stock | USD 0.78 0.01 1.27% |
PerformanceWeakest
| Odds Of DistressRisky
|
Biofrontera is trading at 0.78 as of the 14th of February 2026. This is a 1.27 percent decrease since the beginning of the trading day. The stock's open price was 0.79. Biofrontera has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of November 2025 and ending today, the 14th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of October 2021 | Category Healthcare | Classification Health Care |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. The company has 11.65 M outstanding shares of which 141.32 K shares are currently shorted by private and institutional investors with about 0.34 trading days to cover. More on Biofrontera
Moving against Biofrontera Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Biofrontera Stock Highlights
| President CEO | Hermann Luebbert | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDebt leverage enables Biofrontera to amplify potential investment gains using borrowed funds. Evaluating debt relative to total assets helps investors assess Biofrontera's financial structure and understand the extent to which Biofrontera's operations depend on creditor capital.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biofrontera (BFRI) is traded on NASDAQ Exchange in USA and employs 92 people. Biofrontera is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.2 M. Biofrontera conducts business under Biotechnology sector and is part of Health Care industry. The entity has 11.65 M outstanding shares of which 141.32 K shares are currently shorted by private and institutional investors with about 0.34 trading days to cover.
Biofrontera currently holds about 31.91 M in cash with (10.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Biofrontera Probability Of Bankruptcy
Ownership AllocationBiofrontera shows 12.18 percent of its outstanding shares held by insiders and 23.93 percent owned by other corporate entities.
Check Biofrontera Ownership Details
Biofrontera Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2025-03-31 | 0.0 | |
| Citadel Advisors Llc | 2025-06-30 | 0.0 | |
| Millennium Management Llc | 2025-03-31 | 0.0 | |
| Scotia Capital Inc | 2025-03-31 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 | |
| Jpmorgan Chase & Co | 2025-06-30 | 0.0 | |
| Advisor Group Holdings, Inc. | 2025-03-31 | 0.0 | |
| Two Sigma Securities, Llc | 2025-06-30 | 0.0 | |
| Rosalind Advisors, Inc. | 2025-06-30 | 976.4 K | |
| Aigh Capital Management, Llc | 2025-06-30 | 974.5 K | |
| Geode Capital Management, Llc | 2025-06-30 | 40.4 K |
Biofrontera Historical Income Statement
Biofrontera Stock Against Markets
Biofrontera Corporate Management
| Daniel JD | General Compliance | Profile | |
| Jon MBA | Vice Affairs | Profile | |
| Erica CPA | COO, CEO | Profile | |
| Jeff Holm | Head Devel | Profile | |
| Mark Baldyga | Head Marketing | Profile | |
| Alycia Torres | Vice Administration | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is there potential for Biotechnology market expansion? Will Biofrontera introduce new products? Factors like these will boost the valuation of Biofrontera. Projected growth potential of Biofrontera fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
Understanding Biofrontera requires distinguishing between market price and book value, where the latter reflects Biofrontera's accounting equity. The concept of intrinsic value - what Biofrontera's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Biofrontera's price substantially above or below its fundamental value.
It's important to distinguish between Biofrontera's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biofrontera should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biofrontera's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.